Saudi Gazette report
RIYADH — The Saudi Food & Drug Authority (SFDA) reaffirmed on Tuesday that it has so far not received any reports regarding cases of blood clots or thrombosis from among those who received coronavirus vaccine shots, Saudi Press Agency reported.
In the meantime, over 2.3 million doses of vaccines have been administered in various regions of the Kingdom so far.
The SFDA statement came in the wake of reports about the suspension of the use of AstraZeneca vaccine by some European countries following reports of dangerous blood clots in some recipients, though the company and the World Health Organization (WHO) as well as the European regulators have said there is no evidence the shot is to blame.
The SFDA said in a statement that it is continuously following up the safety of COVID-19 vaccines in the Kingdom and this is through checking and studying the cases of side effects, scientific proofs, and relevant data that are available at the local and international level and that is in coordination with the regulatory bodies and the Ministry of Health officials.
“The authority also follows up the safety of the vaccines with the manufacturing companies, the Ministry of Health and international regulatory departments, through its membership of the International Coalition of Medicines Regulatory Authorities (ICMRA), consisting of over 30 bodies, in collaboration with WHO that periodically meets to exchange data and information over the vaccines as well as their side-effects."
"In the event of having any new developments pertaining to vaccines and their safety, they will be announced through its official channels,” the authority said while calling on everyone to take the news from their authentic sources."
The SFDA instructed all community members and health practitioners to inform the National Vigilance Center about the side effects of coronavirus vaccines via the link:(https://ade.sfda.gov.sa/Covid/CovidRequest) or by the following means of reporting: Unified number of SFDA 1999; mail of the National Vigilance Center (npc.drug@sfda.gov.sa), and SFDA application “Tumni.”
